Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
K333
- Development stage
- Preclinical
- Lead developer
- Beijing Luzhu Biotechnology
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
K333 is a preclinical bispecific antibody developed by Beijing Luzhu Biotechnology for the treatment of myeloid leukemia. It is designed to simultaneously bind to CD33, a surface antigen highly expressed on myeloid leukemia cells, and CD3, a component of the T-cell receptor complex. By bridging these two targets, K333 redirects and activates cytotoxic T cells to specifically target and eliminate CD33-positive malignant cells. This T-cell engager approach aims to provide a potent and targeted immunotherapy for patients with myeloid malignancies, such as acute myeloid leukemia (AML).
- Other names
- CD33-CD3 Bispecific Antibody InjectionCD-33-CD3 Bispecific Antibody InjectionCD 33-CD3 Bispecific Antibody InjectionCD33xCD3 bispecific antibodyCD-33xCD3 bispecific antibodyCD 33xCD3 bispecific antibody
02
Targets
CD33 (Myeloid cell surface antigen CD33)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on K333.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on K333.